Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (441-450 of 598) with videos related to

Pageof 60
Sort By:
Leukemia|July 16, 2024
FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cellsAnna Sperk, Antje Gabriel, Daniela Koch, et al.
Clinical Chemistry|August 23, 2008
Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH studyAlexander Kohlmann, Elisabeth Haschke-Becher, Barbara Wimmer, et al.
Experimental Hematology & Oncology|April 25, 2019
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored doseStefanie Jilg, Richard T Hauch, Johanna Kauschinger, et al.
Research Square|March 22, 2023
Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid NeoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
British Journal of Haematology|June 25, 2020
Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KITKhalid Shoumariyeh, Saskia Hussung, Christoph Niemöller, et al.
Nature Communications|October 4, 2023
TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expressionElizabeth Heyes, Anna S Wilhelmson, Anne Wenzel, et al.
British Journal of Haematology|September 4, 2010
A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology FacultyGina Zini, Barbara Bain, Peter Bettelheim, et al.
Research Square|April 24, 2023
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblastsIn Young Choi, Jonathan Ling, Jian Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.
Iscience|March 17, 2023
A multimodal analysis of genomic and RNA splicing features in myeloid malignanciesArda Durmaz, Carmelo Gurnari, Courtney E Hershberger, et al.
Pageof 60

Showing results (441-450 of 598) with videos related to

Sort By:
Pageof 60
Leukemia|July 16, 2024
FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cellsAnna Sperk, Antje Gabriel, Daniela Koch, et al.
Clinical Chemistry|August 23, 2008
Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH studyAlexander Kohlmann, Elisabeth Haschke-Becher, Barbara Wimmer, et al.
Experimental Hematology & Oncology|April 25, 2019
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored doseStefanie Jilg, Richard T Hauch, Johanna Kauschinger, et al.
Research Square|March 22, 2023
Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid NeoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
British Journal of Haematology|June 25, 2020
Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KITKhalid Shoumariyeh, Saskia Hussung, Christoph Niemöller, et al.
Nature Communications|October 4, 2023
TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expressionElizabeth Heyes, Anna S Wilhelmson, Anne Wenzel, et al.
British Journal of Haematology|September 4, 2010
A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology FacultyGina Zini, Barbara Bain, Peter Bettelheim, et al.
Research Square|April 24, 2023
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblastsIn Young Choi, Jonathan Ling, Jian Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.
Iscience|March 17, 2023
A multimodal analysis of genomic and RNA splicing features in myeloid malignanciesArda Durmaz, Carmelo Gurnari, Courtney E Hershberger, et al.
Pageof 60